These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 26314532)

  • 81. Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study.
    Weisz G; Smilowitz NR; Kirtane AJ; Rinaldi MJ; Parvataneni R; Xu K; Stuckey TD; Maehara A; Witzenbichler B; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Mehran R; Stone GW
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26458411
    [TBL] [Abstract][Full Text] [Related]  

  • 82. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
    Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
    Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients.
    Shimizu A; Sonoda S; Muraoka Y; Setoyama K; Inoue K; Miura T; Anai R; Sanuki Y; Miyamoto T; Oginosawa Y; Tsuda Y; Araki M; Otsuji Y
    J Cardiol; 2019 Jun; 73(6):470-478. PubMed ID: 30591321
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and Thrombosis.
    Sharma SK; Baber U
    J Am Coll Cardiol; 2015 Sep; 66(9):1046-9. PubMed ID: 26314533
    [No Abstract]   [Full Text] [Related]  

  • 86. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome.
    Harskamp RE; Kuijt WJ; Damman P; Beijk MA; Grundeken MJ; Woudstra P; Tijssen JG; de Winter RJ
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):203-9. PubMed ID: 22508617
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Drug-eluting stents versus bare metal stents prior to noncardiac surgery.
    Bangalore S; Silbaugh TS; Normand SL; Lovett AF; Welt FG; Resnic FS
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):533-41. PubMed ID: 25059742
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
    Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
    Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
    Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
    [TBL] [Abstract][Full Text] [Related]  

  • 92. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Liang J; Wang Z; Shi D; Liu Y; Zhao Y; Han H; Li Y; Liu W; Zhang L; Yang L; Zhou Y
    Angiology; 2015 Apr; 66(4):319-25. PubMed ID: 24913197
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Percutaneous coronary intervention of bifurcation lesions and platelet reactivity.
    Redfors B; Généreux P; Witzenbichler B; Kirtane AJ; Maehara A; Weisz G; Madhavan MV; McAndrew T; Mehran R; Stone GW
    Int J Cardiol; 2018 Jan; 250():92-97. PubMed ID: 29074039
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Matteau A; Yeh RW; Camenzind E; Steg PG; Wijns W; Mills J; Gershlick A; de Belder M; Ducrocq G; Mauri L
    Am J Cardiol; 2015 Sep; 116(5):686-93. PubMed ID: 26187674
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial.
    Farooq V; Serruys PW; Bourantas C; Vranckx P; Diletti R; Garcia Garcia HM; Holmes DR; Kappetein AP; Mack M; Feldman T; Morice MC; Colombo A; Morel MA; de Vries T; van Es GA; Steyerberg EW; Dawkins KD; Mohr FW; James S; Ståhle E
    Eur Heart J; 2012 Dec; 33(24):3105-13. PubMed ID: 23103663
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
    Price MJ; Berger PB; Angiolillo DJ; Teirstein PS; Tanguay JF; Kandzari DE; Cannon CP; Topol EJ
    Am Heart J; 2009 May; 157(5):818-24, 824.e1. PubMed ID: 19376306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.